Sequential use of indium-111 labeled monoclonal antibodies 96. 5 and ZME-018 does not increase detection sensitivity for metastatic melanoma

Journal Article · Mon May 01 04:00:00 EDT 1989 · Clinical Nuclear Medicine; (USA)

DOI:https://doi.org/10.1097/00003072-198905000-00011· OSTI ID:5640635

Frontiera, M; Murray, J L; Lamki, L; Thomas, J; Satterlee, W; Schmelter, R; Rosenblum, M G; Khazaeli, M B; Unger, M W; Robinson, W A ^[1]

---

1. Univ. of Colorado Health Sciences Center, Denver (USA)

Two indium-111 labeled anti-melanoma murine monoclonal antibodies (MAb), 96.5 and ZME-018, each recognizing separate antigens on melanoma cells, were administered intravenously to 17 patients with melanoma in a sequential fashion to determine whether: (1) additional tumor sites could be imaged with the combination compared to a single Mab; (2) the first MAb influenced the biodistribution and tumor localization of the second; and (3) significantly toxicity occurred with the combination. Patients were randomized to receive either 96.5, followed by ZME-018, ZME-018 followed by 96.5, or each MAb followed by itself (controls). Infusions of the second MAb occurred 10 days after the first infusion. Gamma camera images were obtained 72 hours after each antibody infusion. There were 139 known metastatic sites of which 72 lesions were localized by either MAb for an overall sensitivity of 52%. The detection rate was higher when lesions only greater than 1.5 cm were considered. Imaging results were independent of MAb administration sequence. When ZME-018 was given as the first infusion, when ZME-018 was given as a second infusion (p = NS). However, mean sensitivities using 96.5 as the first or second infusion were 48% and 66% respectively (p = NS). There was not a significant number of sites detected by MAb 2 that were missed by MAb 1. Human anti-murine antibody (HAMA) response occurred in seven of eight patients studied; two patients who experienced toxicity had levels of HAMA greater than 2000 ng/ml. We conclude that the use of these two murine anti-melanoma monoclonal antibodies given in sequential fashion did not significantly change the imaging sensitivity from that seen with each individual antibody.

• OSTI ID: 5640635
• Journal Information: Clinical Nuclear Medicine; (USA), Journal Name: Clinical Nuclear Medicine; (USA) Vol. 14:5; ISSN CNMED; ISSN 0363-9762
• Country of Publication: United States
• Language: English

Related Subjects

550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BETA DECAY RADIOISOTOPES
BIOLOGICAL HALF-LIFE
CAMERAS
COMPARATIVE EVALUATIONS
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DIAGNOSIS
DIAGNOSTIC TECHNIQUES
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
GAMMA CAMERAS
INDIUM 111
INDIUM ISOTOPES
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
LABELLING
MELANOMAS
METASTASES
MINUTES LIVING RADIOISOTOPES
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEI
ODD-EVEN NUCLEI
PATIENTS
RADIOIMMUNODETECTION
RADIOIMMUNOSCINTIGRAPHY
RADIOISOTOPE SCANNING
RADIOISOTOPES
SCINTISCANNING
SENSITIVITY ANALYSIS
TOXICITY
TRACER TECHNIQUES